Home > Urology > EAU 2020 > Prostate Cancer & Imaging > ARAMIS subgroup analysis: darolutamide benefits across PSADT groups

ARAMIS subgroup analysis: darolutamide benefits across PSADT groups

Principal Investigator
Prof. Martin Bögemann, University of Münster, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EAU 2020
Trial
Phase 3, ARAMIS
Prof. Martin Bögemann (University of Münster, Germany) presented a subgroup analysis of the ARAMIS trial (darolutamide vs placebo), which stratified patients into risk groups based on their prostate-specific antigen doubling time (PSADT), comparing safety and efficacy in patients with PSADTs of ≤6 months versus those with PSADTs >6-10 months [1,2]. Darolutamide demonstrated similar benefits in reducing metastases and death in both the PSADT ≤6 months and >6-10 months subgroups. The safety profile of the PSADT >6-10 months was similar to PSADT ≤6 months. ARAMIS was a randomised, double-blind, placebo-controlled, phase 3 trial in men with non-metastatic castration-resistant prostate cancer (nmCRP...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on